eEF2K promotes tumor growth and progression and more importantly, in vivo inhibition of eEF2K led to significant suppression of tumor growth in multiple PDAC tumor models in mice with no observed toxicity, suggesting that eEF2K is an actionable novel target in PDAC. The gene discussed is EEF2K; the disease is neoplasm.